OGN
HEALTHCAREOrganon & Company
$13.41+0.06 (+0.45%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving OGN Today?
No stock-specific AI insight has been generated for OGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.69$13.44
$13.41
Fundamentals
Market Cap$3.5B
P/E Ratio14.4
EPS$0.93
Dividend Yield0.01%
Dividend / Share$0.08
ROE0.3%
Profit Margin0.0%
Debt / Equity—
Trading
Volume8.3M
Avg Volume (10D)—
Shares Outstanding262.6M
OGN News
22 articles- Organon Buyout By Sun Pharma Shifts Focus To Cash Value And TimingYahoo Finance·May 7, 2026
- Lilly, Gilead lead pharma’s M&A boomPharmavoice·May 7, 2026
- Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance·May 4, 2026
- Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens BankruptcyBenzinga·May 1, 2026
- Organon (OGN)’s Investors React Strongly as Sun Pharma Bets Big on Specialty Drug ExpansionYahoo Finance·May 1, 2026
- Organon (NYSE:OGN) Misses Q1 CY2026 Revenue EstimatesYahoo Finance·Apr 30, 2026
- Jim Cramer Says “Organon’s Done” Upon a Caller’s InquiryYahoo Finance·Apr 30, 2026
- Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·Apr 30, 2026
- Organon (OGN) Q1 Earnings and Revenues Miss EstimatesYahoo Finance·Apr 30, 2026
- Organon Reports Results for the First Quarter Ended March 31, 2026Yahoo Finance·Apr 30, 2026
- European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in EuropeYahoo Finance·Apr 29, 2026
- Organon Cancels First Quarter Earnings CallYahoo Finance·Apr 29, 2026
- Micron initiated, Rambus downgraded: Wall Street's top analyst callsYahoo Finance·Apr 28, 2026
- Company News for Apr 28, 2026Yahoo Finance·Apr 28, 2026
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Homes 4 Rent, BP, Fortis, International Business Machines, Micron Technology, Nucor, Opendoor Technologies, Rambus, and More247 Wall St·Apr 28, 2026
- As biosimilars gain US traction, patent thickets are under more scrutinyPharmavoice·Apr 28, 2026
- Organon & Co. (OGN) Soars to 52-Week High on $11.75-Billion Sun MergerYahoo Finance·Apr 28, 2026
- Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc.·Apr 28, 2026
- Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARCYahoo Finance·Apr 28, 2026
- Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash DealThe Motley Fool·Apr 27, 2026
- Nasdaq, S&P 500 Reach New Peaks; Oil RisesYahoo Finance·Apr 27, 2026
- Sun Pharma Nears Final Offer For Organon In Largest Overseas BetBenzinga·Apr 10, 2026
All 22 articles loaded
Price Data
Open$13.34
Previous Close$13.35
Day High$13.44
Day Low$13.33
52 Week High$13.44
52 Week Low$5.69
52-Week Range
$5.69$13.44
$13.41
Fundamentals
Market Cap$3.5B
P/E Ratio14.4
EPS$0.93
Dividend Yield0.01%
Dividend / Share$0.08
ROE0.3%
Profit Margin0.0%
Debt / Equity—
Trading
Volume8.3M
Avg Volume (10D)—
Shares Outstanding262.6M
About Organon & Company
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—